- Home
- ATRA vs NTRB Comparison
ATRA vs NTRB Comparison
Compare ATRA & NTRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ATRA | NTRB |
|---|---|---|
| Founded | 2012 | 2016 |
| Country | United States | United States |
| Employees | N/A | 3 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Industrial Specialties |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.9M | 42.4M |
| IPO Year | 2014 | N/A |
Fundamental Metrics
Financial Performance| Metric | ATRA | NTRB |
|---|---|---|
| Price | $10.34 | $3.56 |
| Analyst Decision | Sell | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $5.00 | N/A |
| AVG Volume (30 Days) | ★ 3.2M | 9.1K |
| Earning Date | 05-13-2026 | 05-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 122.52 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $120,772,000.00 | N/A |
| Revenue This Year | N/A | $30.17 |
| Revenue Next Year | N/A | $3,394.36 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.92 | $3.40 |
| 52 Week High | $19.15 | $11.68 |
Technical Indicators
Market Signals| Indicator | ATRA | NTRB |
|---|---|---|
| Relative Strength Index (RSI) | 67.90 | 38.01 |
| Support Level | $4.35 | N/A |
| Resistance Level | $12.91 | $4.24 |
| Average True Range (ATR) | 1.45 | 0.15 |
| MACD | 0.06 | -0.01 |
| Stochastic Oscillator | 59.47 | 0.62 |
Price Performance
Historical ComparisonAbout ATRA Atara Biotherapeutics Inc.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).
About NTRB Nutriband Inc.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. Company operates in two reportable segments namely, Sales of Goods and Services. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.